LENSAR Earnings Call Transcripts
Fiscal Year 2026
-
Revenue declined 5% year-over-year due to lower system sales, but recurring revenue grew 9% and now represents 94% of total revenue. The company is rebuilding momentum post-merger termination, with international placements resuming and strong recurring revenue expected to drive future growth.
Fiscal Year 2025
-
2025 saw strong recurring revenue and procedure growth despite acquisition-related disruptions, with LENSAR regaining independence and focusing on expanding its installed base and international reach. Gross margins remained healthy, and positive adjusted EBITDA was achieved.
Fiscal Year 2024
-
Record revenue and system placements in 2024 drove 27% annual growth, with recurring revenue exceeding $40 million and strong U.S. and international expansion. Positive adjusted EBITDA was achieved, and 2025 guidance calls for even higher revenue growth and continued market share gains.
-
Record Q3 with 38% revenue growth and 24 new ALLY system placements, driven by international expansion and strong recurring revenue. U.S. procedure market share rose to 20%, with Q4 and 2025 growth expected as recent installations ramp up.
-
ALLY's advanced imaging and AI-driven laser system is transforming cataract surgery, delivering superior clinical outcomes, significant cost savings, and increased revenues for surgical centers and surgeons. Rapid U.S. market share gains and international expansion signal strong growth potential.
-
Record Q2 with 17 ALLY placements and $12.6M revenue, up 5% year-over-year, driven by strong U.S. and global procedure growth. EU and Taiwan clearances enable international expansion, with robust backlog and positive adjusted EBITDA.